Nanotherapeutic Technologies to Target Common Brain Cancer
Glioblastoma (GBM) is a malignant brain cancer in adults with a median survival period of 15 months from the point of diagnosis. Residual tumor cells that remain beyond the margins of every GBM resection are resistant to postsurgical therapy and are the driving force of mortality. These residual tumor cells reach extensive brain tissues, [...]









